CHEMO ESPAÑA, S.L. – Trademark Portfolio
Entity Type: 99
CHEMO ESPAÑA, S.L. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 5 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include XIROMED and PREGNITUDE. The owner is based in Madrid.
C/ Quintanapalla, 2-4 FL
Madrid 28050 , ES
Showing of trademarks Trademarks
Trademark Classifications
CHEMO ESPAÑA, S.L.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does CHEMO ESPAÑA, S.L. have?
CHEMO ESPAÑA, S.L. has 11 U.S. trademarks filed with the USPTO. Of these, 3 registered, 7 abandoned.
What trademark classes does CHEMO ESPAÑA, S.L. file in?
CHEMO ESPAÑA, S.L. files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 39 (Transportation & Storage). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CHEMO ESPAÑA, S.L.'s most well-known trademarks?
CHEMO ESPAÑA, S.L.'s registered trademark portfolio includes well-known marks such as XIROMED and PREGNITUDE. These are among 3 currently registered trademarks in the portfolio.
What is CHEMO ESPAÑA, S.L.'s trademark registration success rate?
CHEMO ESPAÑA, S.L. has a 30% trademark registration rate, with 3 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.